Parecer de pré-exame
#6.23
09/20/2022
RPI 2698
Application data
Number
112020007476Type
Filing
Publication
PCT
US2018056801 Patent grant document available
We have the complete official document for this filing, as published by INPI.
Access the documentThe INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.
Latest action published by the INPI: 09/20/2022. We update with every new RPI gazette, published weekly.
Applicants
DICERNA PHARMACEUTICALS, INC.
US
Inventors
M. A. (pessoa física)
US
M. K. (pessoa física)
US
IPC Classification
Priority claims
US
62/575,358 · 10/20/2017
Abstract
Este pedido refere-se a oligonucleotídeos potentes úteis para reduzir a expressão de HBsAg e tratar infecções por HBV.
Publications in the Brazilian Industrial Property Gazette (RPI).
#6.23
09/20/2022
RPI 2698
#15.35
12/07/2021
RPI 2657
#1.3
10/27/2020
RPI 2599
#1.1
09/15/2020
RPI 2593
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.